The synthesis of 5'-methylene-[1, 4]-triazole-substituted aminoribosyl uridines is described from a unique epoxide regioselectively opened by acetylide or azide ions. Biological evaluation was performed and was rationalized by molecular modeling.
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Organic & Biomolecular Chemistry www.rsc.org/obc Introduction In the context of the increasing resistance 1 of bacteria to commonly used antibiotics and of the emergence of multidrug resistant bacterial strains, it is of prime importance to develop antibiotics with new mechanisms of action. Several strategies are developed for discovering new antibiotics, which notably include the identification of new antibacterial targets by genomics approaches and the screening of synthetic libraries on these targets. 2 However, a main drawback with the latter strategy relies on the limited chemical diversity of the available libraries and on the use of non-validated and isolated bacterial targets. 3 A complementary approach deals with the manipulation of genes encoding enzymes involved in polyketides and non-ribosomal peptides, in order to generate new derivatives. 4 Indeed, many useful antibiotics belong to the latter two biosynthetic classes. New targets are also looked for in already known biological processes such as for example folate biosynthesis, 5 fatty acid biosynthesis, 6 peptide deformylase 7 and transfer ribonucleic acid synthetases. 8 The bacterial cell wall is also particularly interesting in this respect. Indeed, the multiple enzymes involved in peptidoglycan biosynthesis, 9 which are essential and specific of the bacterial world, constitute ideal targets for the search of new antibiotics, the inhibition of any step in this pathway provoking an arrest of growth and cell lysis. Thus, β-lactams and lipoglycopeptides are well-known antibiotics which interfere with the late polymerization steps of peptidoglycan biosynthesis. However, the ever increasing number of resistance mechanisms developed or acquired by pathogens towards these antibacterial agents 10 imposes us to focus on upstream biosynthetic steps as potential alternative drug targets. For several years, our group focused on the MraY transferase, an integral membrane protein that is not targeted by any drug in clinical use so far, a major advantage expected to delay the emergence of resistance. The 3D structure of MraY was unknown until recently, due principally to its transmembrane nature. Nevertheless, the challenge has recently been addressed and the 3D crystal structure of MraY from Aquifex aeolicus (MraY AA ) has been determined 11 confirming key structural features that had been previously identified. 12, 13 This enzyme, which catalyzes the first membrane-associated step of peptidoglycan biosynthesis, has been demonstrated essential 14 and is ubiquitous in the bacterial kingdom. It transfers the phospho-N-acetylmuramoyl-pentapeptide (P-MurNAc-pentapeptide) moiety from the cytoplasmic precursor UDP-MurNAc-pentapeptide to the membrane lipid acceptor undecaprenyl-phosphate (C 55 -P), generating C 55 -pyrophosphoryl-MurNAcpentapeptide (lipid I) and uridine monophosphate (UMP) (Fig. 1 ). 12 Fig. 1 Reaction catalyzed by the bacterial transferase MraY. The protein is represented according to PDB code 4J72 of MraY AA , including the catalytic magnesium (yellow ball).
In addition to few non nucleosidic compounds recently described, 15 several families of natural nucleoside antibiotics such as FR-900493, 16 liposidomycins, 17 caprazamycins 18 and muraymycins 19 (Fig. 2 ) have been identified as MraY inhibitors and displayed interesting antibacterial activities. 20 Elegant synthetic approaches toward these compounds have been reported. 21, 22 The common aminoribosyl-Ouridine scaffold shared by the natural nucleoside inhibitors has been proven to be essential for biological activity. 23 Based on this aminoribosyl-O-uridine frame, our goal was to develop powerful MraY inhibitors, displaying simplified structure as compared to that of natural inhibitors, and endowed with antibacterial activity.
We here report the diversity-oriented synthesis of new MraY inhibitors ( Fig. 3) , containing either a Ctriazole (compounds II) or a N-triazole (compounds III). Both families exhibit a supplementary methylene group between the aminoribosyl uridine scaffold and the triazole linker as compared to the 5'-triazolesubstituted aminoribosyl uridines (compounds I) we previously described. 24 The enhanced flexibility of compounds II and III was expected to improve the positioning of the resulting inhibitors within the active site of MraY and to result in a better inhibitory activity. 25 Identical R groups were used in both series allowing a comparison of the respective impacts of C-and N-triazole linkers. The in vitro and in cellulo biological activity of compounds I, II and III was evaluated and a molecular modeling study was performed to rationalize the obtained in vitro activities. 
Results and discussion

Chemical synthesis
The retrosynthesis we designed ( Fig. 4 ) towards the targeted inhibitors II and III relies on the Cu(I)catalyzed azide-alkyne cycloaddition 26 (CuAAC) involving individual azides or alkynes and complementary 5'-alkynylmethylenyl-aminoribosyl uridine A or 5'-azidomethylenyl-aminoribosyl uridine B, respectively. These building blocks A and B could result from O-glycosylation of the corresponding homopropargylic alcohol C or azidomethyl alcohol D by a known anomerically activated and amine protected 5-amino-5deoxy-D-ribofuranoside. Both alcohols C and D could come from a unique epoxide E. We recently described the multi-gram scale synthesis of epoxide 1 and its regioselective opening by various carbo-and hetero-nucleophiles. 27 In particular, nucleophilic opening of the epoxide 1 by lithium trimethylsilylacetylide in the presence of BF 3 .Et 2 O furnished the corresponding trimethylsilyl homopropargylic alcohol 27 that was deprotected in the presence of potassium carbonate in methanol to give 2 in 71% overall yield (Scheme 1). In a complementary manner, opening of the epoxide 1 by sodium azide in the presence of ammonium chloride afforded the azido alcohol 3 27 in 85% yield. Both alcohols 2 and 3 were next submitted to glycosylation with the known amino ribose derivative 4, 24 activated as a fluoride in anomeric position and protected at C 5' as a phthalimido group to prevent any side reaction during the further CuAAC reaction. This reaction was carried out in the presence of boron trifluoride etherate 28 at -78 °C in CH 2 Cl 2 to provide the phthalimidoribosyl uridine derivatives 5 and 6 in 61% and 41% isolated yields, with a good β/α diastereoselectivity (80/20 and 85/15, respectively) thanks to the isopentylidene protective group of the diol, hindering the α face of the ribosyl donor. Assignment of anomers for compounds 5 and 6 was made according to distinguishing characteristic 1 H NMR signals for H 1" (a singlet at 5.24 ppm for the major  anomers 5 and 6 and a doublet at 5.29 and 5.33 ppm ( 3 J H1"-H2" = 2.5 Hz) for their corresponding minor α anomers, respectively). Scheme 1 Synthesis of alkyne 5 and azide 6. Reagents and conditions: a) Trimethylsilylacetylene, n-BuLi, BF 3 .OEt 2 , THF, -78 °C to -10 °C, 16 h, 77%; b) K 2 CO 3 , MeOH, 92%; c) 4, BF 3 .EtO 2 , M.S. 4 Å, CH 2 Cl 2 , -78°C, 81% as a 80/20 /α mixture, 61% isolated for 5, 55% as a 85/15 β/α mixture, 41% isolated for 6; (d) NaN 3 , NH 4 Cl, DMF, 70 °C, 16 h, 85%. With these key intermediates in hands, we next turned to the preparation of the complementary fragments for CuAAC, azido and alkynes building blocks with various structures and polarity ( Fig. 4) . Thus, apolar aliphatic or aromatic azides and alkynes 7a-b and 8a-b and polar hydroxylalkyl azides and alkynes with various chain lengths 7c-d and 8c-d were selected. Highly hydrophilic PEG-containing azide and alkyne 7e and 8e, prone to enhance water solubility, and phthalimidoalkyl azide and alkyne 7f and 8f, as masked primary amines, were also chosen. In addition, a few benzophenone containing azides and alkynes 7g-h 24 and 8 g-h were included in the series. Indeed, the related compounds I (Fig. 3) bearing such a photoactivable group revealed promising inhibition of MraY activity 24 and the benzophenone moiety could further be exploited to promote, upon irradiation, the formation of a covalent linkage with the enzyme. Such an irreversible MraY-inhibitor complex should enhance the stability of the protein and promote its crystallization that would be a major leap for rational drug design of new antibiotics. All these complementary fragments were either purchased from commercial sources or synthesized in few steps from alcohols or bromide derivatives. The synthesis of azides 7b,d,f and alkynes 8b-d,f-h is depicted in Scheme 2. From the mesylate 9, readily obtained from phenyl decanol in 91% yield, the azide 7b was prepared by direct nucleophilic substitution by sodium azide, while the nucleophilic substitution of the mesylate by lithium trimethylsilyl acetylide revealed unsuccessful. Alkyne introduction required the intermediate formation of the corresponding bromide 10 followed by its substitution by lithium acetylide leading to 11 and subsequent TMS deprotection to provide the alkyne 8b in 62% overall yield from 9. The azide 7d resulted from bromodecanol by sodium azide substitution. The phthalimidoalkyl azide 7f resulted from dimesylate 12 29 followed by nucleophilic substitution with sodium azide to give 13 and subsequent phthalimide introduction. The alkynes 8c,d,f,h were obtained from the corresponding dibromoalcane through substitution with lithium trimethylsilyl acetylide which intermediately gave 14 and 15. The bromo derivative 14 was substituted by potassium acetate to afford 16 that was deprotected by potassium carbonate in methanol to furnish the alcohol 8c. In the same manner, the bromo derivative 15 led to the alcohol 8d through the acetate 17. The phthalimido alkyne 8f and the benzophenone 8h were respectively prepared by nucleophilic substitution of the bromo derivative 15 with phthalimide potassium salt giving 18 and by 4-hydroxy-benzophenone in the presence of potassium carbonate leading to 19, followed by TBAF deprotection. Attempts to prepare the alkyne 21 from the bromo derivative 20 24 by nucleophilic substitution with sodium acetylide or lithium trimethylsilylacetylide resulted either in recovery of unchanged starting material or complete degradation. Finally, the alkyne 8g was synthesized from bromide 20, by copper-promoted coupling 30 with trimethylsilyl acetylene leading to alkyne 21, followed by TMS deprotection in the presence of potassium carbonate in methanol. It is noteworthy that TBAF deprotection exclusively led to the formation of allene 22.
We next turned to the synthesis of the triazole-containing targeted compounds 25a-h and 26a-h (Scheme 3). Thus, azido and alkyne building blocks 5 and 6 were submitted to CuAAC conditions with their complementary partner 7a-h and 8a-h, respectively. The reaction was carried out in the presence of catalytic copper (I) in situ generated from copper sulphate and sodium ascorbate 26 in a 3/1 tert-BuOH/H 2 O mixture with diisopropylethylamine as a base and afforded the expected C-and N-triazoles 23a-h and 24a-h in yields ranging from 43 to 68% (Table 1) . Amine and alcohols deprotections were successively performed by methylamine in methanol and acidic hydrolysis to give the targeted inhibitors 25a-h and 26a-h that were purified by preparative C-18 HPLC and isolated as their TFA salts in 34 to 72% yield over two steps. No trace of degradation product resulting from acidic cleavage of the glycosidic bond was detected. To perform a SAR study of these triazole-containing compounds as inhibitors of the MraY activity, biological activity of the C-and N-triazoles 25a-h and 26a-h (compounds II and III) was evaluated ( Table  2 ) and compared to that of the previously described compounds I 24 (Table 3) Furthermore, to assess the impact of the polarity and the structure of the triazole substituent on the inhibitory activity, the unprotected alkynes 28 and 34 and azide 29 were synthesized as reference compounds (Scheme 4). On the one hand, alkyne 28 and azide 29 were readily prepared by amine and alcohols deprotection of alkyne 5 and azide 6 according to the same conditions as described above for compounds 25 and 26. On the other hand, the alkyne 34 was obtained in three steps involving glycosylation of the propargylic alcohol 31 31 with 5-azidoribosyl fluoride 30 28 as a ribosyl donor to give 32, azide reduction in Staudinger conditions leading to 33 and acidic hydrolysis of ketal protective groups. 
Biological evaluation
The inhibitory activity of compounds I (27a-n), II (25a-h), III (26a-h) and their unprotected precursors (34, 28, 29) , was evaluated on purified MraY transferase. Concerning compounds I (Table 2) , the introduction on the triazole of a short alkyl chain bearing a polar group such as a hydroxyl (27e,f), an amino group (27g), an imidazolyl (27i), a hindered cycloheptyl moiety (27b) or a more complex piperazinopyridine chain (27j), revealed to be detrimental to the inhibitory activity (IC 50 > 1000 µM), as compared to that of the parent compound 34 (IC 50 = 100 µM). Indeed, in this series the best inhibitors were those containing either a benzophenone moiety (27k-n) or an alkyl chain (27a,h) with IC 50 ranging from 50 to 150 µM, showing that an hydrophobic chain of sufficient length permitted to maintain the enzyme inhibition in the 100 µM range. As exemplified for compounds 27c and 27d, a shorter or a more rigid hydrophobic R group led to weaker activities (IC 50 of 250 and 400 µM, respectively). (50 ng) , and the mixture was incubated for 30 min at 37 °C under shaking. The reaction was stopped by heating at 100 °C for 1 min and the radiolabeled substrate (UDP-MurNAc-pentapeptide) and reaction product (lipid I) were separated by TLC on silica gel plates. The radioactive spots were located and quantified with a radioactivity scanner. Data represent the mean of independent triplicate determinations.
b The activities were tested against purified MraY from Aquiflex aeolicus.
Interestingly, the mode of inhibition was investigated and demonstrated competitive towards the nucleotide substrate as exemplified for compound 27k (Fig. 7) with a K i value of 80 µM. The in vitro activity of compounds II and III is depicted in Table 3 . Commercially available tunicamycin from Streptomyces sp. was used as a positive control in the test and resulted in an IC 50 value equal to 0.012 µM. From a general point of view, the inhibitory activity of compounds II and III on the MraY transferase was better than that of compounds I. Furthermore, the general tendency showed that the Ctriazole-containing compounds II were more potent than the corresponding N-triazole-containing compounds III. The inhibitors bearing the longest alkyl chains (25d, 26d) were more potent than their shorter homologs (25c, 26c). For a same length, the compounds containing a hydroxyl group (25d, 26d) were more active than those containing an amino group (25f, 26f). In spite of their enhanced hydrosolubility, PEG-containing inhibitors (25e, 26e) appeared poorly active. However, the introduction of a long hydrophobic chain on the triazole drastically improved the inhibitory activity, yielding IC 50 ranging from 15 to 25 µM for compounds II (25a,b,g,h) and from 25 to 100 µM for compounds III (26a,b,g,h) . For these compounds, in both series, the introduction of a substituted C or N-triazoles improved by up to 10-40 fold the inhibitory potency as compared to that of the parent compounds (28, 29) . The promising results obtained for the inhibitors 25g,h and 26g,h demonstrated a tolerance for rather bulky groups such as benzophenone moieties. The antibacterial activity of compounds I, II, III was evaluated and the data are shown in Table 4 . Several Gram-negative (E. coli ATCC 8730, C. freundii ATCC8090 and P. aeruginosa ATCC 27853) and Gram-positive pathogenic bacterial strains (S. aureus ATCC 25923, E. faecium ATCC 19434) were selected, including a methicillin resistant strain (S. aureus MRSA ATCC 43300). Piperacillin and vancomycin were used as positive control in the tests. Interestingly, 9 out of the 33 tested compounds revealed antibacterial activity with minimum inhibitory concentration (MIC) values of 8-64 µg/mL on the three Gram-positive pathogens and on the Gram-negative P. aeruginosa. The best antibacterial activities were observed for compounds 26h and 27m bearing a hydrophobic decyloxybenzophenone R group with IC 50 values of 25 and 100 µM, respectively ( Table 2 and 3). These promising antibacterial activities were obtained against S. aureus MRSA and the MIC values were 8 µg/mL. Despite the simplicity of the 5' substituent beared by the aminoribosyl uridine scaffold, it is noteworthy that these antibacterial activities are comparable with that reported for muraymycins, natural MraY inhibitors with much more complex structure. ) were prepared in saline solution (NaCl 0.085%) and then diluted 200 fold in MBH. MIC values were determined as the lowest dilution of product showing no visual turbidity.
Molecular Modeling
Our SAR study revealed that a hydrophobic moiety was crucial for the inhibitory activity. To better understand how the synthesized compounds interact with the MraY protein and to evaluate the role of this hydrophobic counterpart, we took advantage that the X-ray crystal structure of MraY from Aquifex aeolicus (MraY AA , PDB code: 4J72) had been recently solved, 11 paving the way for molecular docking studies. This structure revealed an active site opened towards the cytoplasm. It comprises a magnesium cation, 10 transmembrane helices (TM1-10) and a deep hydrophobic pocket localized in the transmembrane domain and surrounded by TM5 and TM9 ( Fig. 8 ). We thus anticipated that this hydrophobic groove could play a major role in the interaction of our compounds, through their hydrophobic tail, within the enzyme active site. Fig. 8 The active site of MraY AA . Molecular surface of MraY was obtained by the superimposition of atom-centered spheres, where the spheres' radii are given by the atomic van der Waals radii. The putative active site (red circle) described by Chung et al. 11 is located predominantly in the cytosolic extra-membranar portion and partially into the trans-membrane domain of the protein. The catalytic Mg 2+ is represented by a green sphere and the hydrophobic groove is shown by a blue arrow. The access of this cleft is monitored by the Leu191 (in yellow).
After preparation of both protein and ligands (compounds 25-27), we performed a blind docking study of all compounds in the putative ligand binding site centered to the magnesium ion (i.e. Mg 2+ , and key residus characterized by Bouhss et al. 13 such as Asp117 and Asp118). In parallel, all compounds were divided into three batches according to their in vitro potency: active compounds with an IC 50 below or equal to 25 µM (compounds 25a,b,g,h and 26h), weakly active compounds which have no activity at 250 µM (compounds 25c,e, 26c,e and 27b,d-g,i,j) and an intermediate set (compounds 25d,f, 26a,b,d,f,g and 27a,c,h,k-n) with IC 50 values ranging from 25 to 250 µM. 200 conformers of compounds were generated using Caesar protocol of Discovery studio 4.1 software 32 and have been docked using cDOCKER protocol. 33 Finally, 5840 poses were generated after conformers docking and have been analysed based on their interactions with hydrophobic groove residues. In particular, we monitored poses in which compounds bind with the key leucine residue (Leu191) localized at the entrance of the groove (Figure 8 ). Comparison using scoring function appeared to be inappropriate in our case because of the micromolar activities of our compounds (IC 50 > 10 µM), so that we selected the best interaction energy poses (based on cDOCKER Interaction Energy 33 ) for our binding studies. Interestingly, our study revealed that an interaction with Leu191, and consequently with the hydrophobic groove, was sufficient to discriminate between active compounds and others, either intermediate or weakly active, as illustrated with compounds 25a and 25f ( Fig. 9 ). Furthermore, the results of docking experiments showed that active compounds bound according to two modes. These two binding modes are illustrated with compound 25a (Figure 10 ). Both of them revealed a good interaction between the amino-ribosyl part of inhibitor 25a and the Mg 2+ cation (green ball, Fig. 10 ) as well as a various and complex network of low electrostatic interactions with residues located in the active site and known to be important for substrate recognition, 13 such as Asp265 or Lys121. A major difference between both modes of interaction is the positioning of active compounds within the active site. Indeed, the interaction with the hydrophobic groove can involve the hydrophobic tail of the active inhibitors (Mode A, Fig. 10a ), as one can expect, or, more surprisingly, their uracil moiety (Mode B, Fig. 10b ). The effect of introducing a hydrophobic moiety on an aminoribosyl scaffold was already reported. 34, 35 On the one hand, Dini et al. 34 reported an interesting SAR study of aminoribosyl uridine derivatives lacking the hydroxyl group at C-3' and bearing various substituents at C-5'. Their study showed that the introduction of an hydrophobic chain at C-5' led to a five to ten-fold increase of in vitro potency compared to that of the parent compound. These results are in good agreement with a positioning of the inhibitors according to the mode A suggested by our docking experiments. On the other hand, Matsuda et al. 35 reported the synthesis of muraymycins analogues with an elaborate urea-dipeptide motif introduced on an aminoacid at the C-5' position of an aminoribosyl uridine scaffold. Biological evaluation of several analogs differing by the hydrophobic chain introduced on this urea-dipeptide was also reported and showed that the presence of a long hydrophobic chain decreased the inhibitory activity by a factor 30, while the antibacterial activity was improved due to a better membrane penetration. According to the authors, this urea-dipeptide moiety could interact with the carbohydrate recognition domain in the cytoplasmic loop 5, while the aminoribosyl moiety could interact with the vicinal Asp located on the cytoplasmic loop 2, close to the magnesium cation. The resulting positioning, locating the uracil moiety next to the hydrophobic groove, would be in good agreement with our binding mode B. Thus, the two modes of binding revealed by our docking study could explain the constrasting conclusions of the SAR reported by Dini and Matsuda.
Conclusion
We report the synthesis of 16 inhibitors of the bacterial transferase MraY displaying a 5'-methylene- [1, 4] -triazole-substituted aminoribosyl uridine structure from a conveniently protected epoxyuridine derivative. Key steps of the synthesis involved the regioselective opening of this epoxide by acetylide or azide ions followed by a sequential -selective glycosylation with a ribosyl donor, Cu(I)-catalyzed azidealkyne cycloaddition with various complementary azide and alkyne partners, to introduce chemical and structural diversity, and deprotection to afford C-triazole (compounds II) or a N-triazole (compounds III). The biological activity of the 16 resulting compounds was evaluated in vitro on purified MraY and in cellulo on different Gram (+) and Gram (-) bacterial strains and was compared to that of 14 previously synthesized compounds lacking the 5' methylene group (compounds I). The latter revealed weakly active on MraY, except those bearing either a benzophenone moiety, for which the IC 50 ranged from 50 to 125 µM, or a hydrophobic chain with IC 50 about 150 µM. In contrast, all compounds II and III proved to be inhibitors of the enzymatic activity of MraY, with IC 50 ranging from 15 to 25 µM for the most potent, showing a meaningful improvement of the inhibitory activity related to the enhanced flexibility of compounds II and III as compared to that of compounds I. A slight superiority of compounds II as compared to compounds III was observed revealing the influence of the positioning of the triazole ring within the active site, the mode of inhibition of these inhibitors having been demonstrated competitive towards the nucleotide substrate. The introduction of a long hydrophobic chain on the triazole drastically improved the inhibitory activity. A molecular modeling study was performed to rationalize the observed structure-activity relationships (SAR), which allowed us to correlate the activity of the most potent compounds with an interaction involving Leu191 of MraY AA and which was consistent with two possible mode of positioning for the most active inhibitors within the enzymatic active site, with either the hydrophobic chain in the hydrophobic groove or the uracil moiety. The antibacterial activity was also evaluated and out of the 30 tested compounds, seven of them exhibited a good activity against Grampositive bacterial pathogens with MIC ranging from 8 to 32 µg/mL, including methicillin resistant Staphylococcus aureus (MRSA).
Experimental General Experimental Methods
When needed, reactions were carried out under an argon atmosphere. They were monitored by thinlayer chromatography with precoated silica on aluminium foil. Flash chromatography was performed with silica gel 60 (40-63 μm) ; the solvent systems are given v/v. Spectroscopic 1 H and 13 C NMR, MS and/or analytical data were obtained using chromatographically homogeneous samples. 1 H NMR (500 MHz) and 13 C NMR (125 MHz) spectra were recorded in CDCl 3 unless indicated. Chemical shifts (δ) are reported in ppm and coupling constants are given in Hz. For each compound, detailed peak assignments have been made according to COSY, HSQC and HMBC experiments. The numbering of molecules is indicated in the supporting information file. Optical rotations were measured with sodium (589 nm) lamp at 20 °C. Melting points were measured on a hot bench. IR spectra were recorded on a FT-IR spectrophotometer and the wavelengths are reported in cm -1 . Purification of tested compounds was achieved by either recrystallization or semi-preparative reverse phase HPLC (column: Cluzeau, C 18 -Stability, 10 µm, 250 mm × 20 mm). Unless indicated, methods used for purification were: method A: flow rate: 15 mL/min, H 2 O-TFA 0.1% / MeOH (60/40 to 10/90 v/v in 12 min); method B: flow rate: 15 mL/min, H 2 O-TFA 0.1% / MeOH (60/40 for 5 min to 10/90 v/v in 10 min). Purity of tested compounds (>95%) was controlled by analytical reverse phase HPLC (column: Cluzeau, C18-Stability, 5 µm, 250 mm × 4.6 mm). Unless indicated, methods used were: method C: flow rate: 1 mL/min, H 2 O-TFA 0.1% / MeOH (60/40 to 10/90 v/v in 12 min) or method D: flow rate: 1 mL/min, H 2 O-TFA 0.1% / MeOH (60/40 for 5 min to 10/90 v/v in 10 minutes). Products were detected at 254 nm; Low resolution mass spectra (LRMS) were recorded with an ion trap mass analyzer under electrospray ionization (ESI) in positive ionization mode detection or atmospheric pressure chemical ionization (APCI). High resolution mass sprectra (HRMS) were recorded with a TOF mass analyzer under electrospray ionization (ESI) in positive ionization mode detection, atmospheric pressure chemical ionization or atmospheric pressure photoionization (APPI). For MraY activity, the radioactive spots were located and quantified with a radioactivity scanner (model Multi-Tracemaster LB285).
Chemical synthesis 5′(S)-C-(Acetylenylmethyl)-2′,3′-di-O-(tert-butyldimethylsilyl) uridine 2.
At -78 °C, to a solution of ethynyltrimethylsilane (2.29 g, 23.35 mmol, 4 equiv.) in dry THF (35 mL) was dropwise added n-BuLi (1.9 M in hexane, 12.3 mL, 23.35 mmol, 4 equiv.) . The resulting solution was stirred at -78 °C for 1 h. At -78 °C were successively added dropwise a solution of epoxide 1 (2.83 g, 5.84 mmol, 1 equiv.) in freshly distillated THF (35 mL) and BF 3 . Et 2 O (2.9 mL, 23. 35 mmol, 4 equiv.) . The resulting solution was allowed to warm from -78°C to -10°C and the mixture was diluted in DCM. Saturated aqueous solution of NH 4 Cl was then added (20 mL) and the aqueous phase was extracted with DCM (3 × 40 mL). The combined organic phases were dried over Na 2 SO 4 , filtered and concentrated in vacuo. Flash chromatography of the residue (Cyclohexane/EtOAc = 8/2 to 7/3) afforded the desired homopropargylic alcohol as a white powder (2.63 g, 77% yield). This compound (2.6 g, 4.46 mmol, 1 equiv) was then dissolved in methanol (52 mL) and potassium carbonate (3.1 g, 22.3 mmol, 5 equiv) was added. The mixture was stirred at r.t. for 2.5 h and quenched by addition of saturated aqueous solution of NH 4 Cl (30 mL). After removal of volatiles in vacuo, the aqueous phase was extracted with EtOAc (5 × 50 mL) and the combined organic layers were dried over Na 2 SO 4 Fluoride 4 (684 mg, 1.96 mmol, 2 equiv) and alkyne 2 (500 mg, 0.98 mmol, 1 equiv) were dried together by coevaporation with toluene (3 × 10 mL) and dissolved in DCM (26 mL). The flask was flushed with argon and molecular sieves 4 Å was added (5 g) in one portion. The suspension was stirred at r.t. for 1 h and then cooled to -78 °C. Boron trifluoride diethyletherate (248 µL, 1.96 mmol, 2 equiv) was added at -78 °C and the reaction media was stirred at this temperature for 10 min and was then allowed to warm to r.t. for 16 h. The reaction mixture was filtered on a celite pad and the cake was washed with DCM (50 mL). The reaction was quenched by addition of a saturated aqueous NaHCO 3 solution (50 mL 
1'',5''-Dideoxy-2'',3''-O-isopentylidene-5''-phthalimido-1''-[2',3'-O-isopropylidene-5'(S)-azidomethyluridinyl]
-β-D-ribofuranose 6. Fluoride 4 (1.19 g, 3.39 mmol, 2.1 equiv) and azide 3 (852 mg, 1.61 mmol, 1 equiv) were dried together by co-evaporation with toluene (3 × 10 mL) and dissolved in DCM (26 mL). The flask was flushed with argon and molecular sieves 4 Å was added (8 g) in one por.t.ion. The suspension was stirred at r.t. for 1 h and then cooled to -78 °C. Boron trifluoride diethyletherate (426 µL, 3.39 mmol, 2.1 equiv) was added at -78 °C and the reaction media was stirred at this temperature for 10 min and was then allowed to warm to r.t. for 16 h. The reaction mixture was filtered on a celite pad and the cake was washed with DCM (50 mL). The reaction was quenched by addition of a saturated aqueous NaHCO 3 solution (50 mL) and the aqueous phase was extracted with DCM (5 × 60 mL). The combined organic layers were dried (Na 2 SO 4 ), filtered and concentrated in vacuo. The resulting white foam was purified by flash chromatography (Toluene/Acetone 95/5) to give the phtalimido-ribosyl-uridine 6 as a β/α mixture (β/α = 85/15) as a white foam (761 mg, 55% combined yield). The β-anomer was isolated with 41% yield: R f 0.52 (Toluene/Acetone 8/2); m.p. 102-106 °C; [α] D -9 (c 0.6, CH 2 Cl 2 ); IR (film) 2928br, 2856br, 1715s, 1698m, 1394m; 1 H NMR  8.45 (br s, 1H, NH), 7.91-7.89 (m, 2H, H 11'' 10-Phenyldecyl methanesulfonate 9. To a solution of 10-phenyldecan-ol (625mg, 2.67 mmol, 1 equiv), in dichloromethane (2 mL 13 C NMR δ 143.0 (C 1 ), 128.5 (C 3 ), 128.4 (C 2 ), 125.7 (C 4 ), 51.7 (C a ), 37.5 (CH 3 ), 36.1 (C j ), 31.6 (C i ), 26.6, 29.4, 29.3, 28.9, 26 .9 (C b, C c , C d , C e , C f , C g, C h ); HRMS ESI + calcd for C 17 H 28 O 3 SNa + (M + Na) + 335.1651, found 335.1652.
1-Bromo-10-phenyl-decane 10. To a solution of mesylate 9 (150 mg, 0.48 mmol, 1 equiv), in acetone (3.0 mL) was added lithium bromide (84 mg, 0.96 mmol, 2.0 equiv). The mixture was refluxed for 2 h, cooled to r.t., and concentrated in vacuo. The residue was filtered through a silica gel pad and washed with DCM (50 mL) to furnish 10 as a colorless oil (137 mg, 96% yield): R f 0.62 (Cyclohexane/EtOAc 9/1); IR (film) 3026w, 2925s, 2853m, 1603w, 1453m, 699s; 1 H NMR δ 7. 30-7.27 (m, 2H, H 3 29.6, 29.6, 29.4, 28.9, 28 .3 (C c , C d , C e , C f , C g, C h ); HRMS APPI calcd for C 16 H 25 Br .+ (M) .+ 296.1140, found 296.1130. Spectral data were in agreement with literature. 36 
12-Phenyl-1-trimethylsilyl-dodec-1-yne 11.
A flame dried flask flushed with argon was cooled to -78 °C and charged with a solution of ethynyltrimethylsilane (413 mg, 4.21 mmol, 2.5 equiv), in dry THF (10 mL). The mixture was stirred at -78 °C for 5 min and n-BuLi was then added dropwise (2.5 M in hexane, 1.69 mL, 4.21 mmol, 2.5 equiv) . The medium was stirred at -78 °C for 1 h and HMPA (731 µL, 4.21 mmol, 1 equiv) was then added. Finally, at -78 °C, to this resulting solution was added dropwise a solution of freshly purified 1-bromo-10-phenyl-decane 10 (500 mg, 1.68 mmol, 1 equiv) in THF (5 mL). The resulting orange solution was stirred at -78 °C and then at r.t. for 16 h, quenched with a saturated aqueous solution of NH 4 Cl (10 mL) and volatiles were removed in vacuo. The aqueous phase was extracted with DCM (3 × 20 mL) and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo. Flash chromatography of the residue (Cyclohexane) afforded alkyne 11 as a colorless oil (387 mg, 73% yield): R f 0.24 (Cyclohexane); IR (film) 2928m, 2848m, 2167w, 1448w, 843m, 744s; 1 H NMR  7. 28-7.24 (m, 2H, H 3ar ), 7.16-7.14 (m, 3H, H 2ar , H 4ar ), 2.58 (t, 2H, J Ha-Hb = 7.5 Hz, H a ), 2.19 (t, 2H, J Hj-Hi = 7.5 Hz, H j ), 1.62-1.56 (m, 2H, H b ), 1.49 (qt, 2H, J Hi-Hj = J Hi-Hh = 7.5 Hz, H i ), 1. 38-1.23 (m, 12H, H c , H d , H e , H f , H g , H h ); 13 C NMR δ 143.1 (C 1ar ), 128.5 (C 3ar ), 128.4 (C 2ar ), 125.7 (C 4ar ), 107.9 (C 2 ), 84.4 (C 1 ), 36.1 (C a ), 31.7 (C b ), 29.6, 29.6, 29.5, 29.2, 28.9, 28.8, 25.5 (C c , C d , C e , C f , C g, C h , C i ), 20.0 (C j ); HRMS APPI Calcd for C 18 H 26 + (M -TMS + H) + 242.2035, found 242.2028.
10-Azido-decyl methanesulfonate 13. To a suspension of dimesylate 12 29 (1 g, 3.03 mmol, 1 equiv), in acetonitrile (16 mL) was added sodium azide (197 mg, 3.03 mmol, 2.5 equiv). The mixture was refluxed for 18 h and cooled to r.t. The precipitate was then filtered out and the filtrate was concentrated in vacuo. 13 C NMR δ, 70.3 (C a ), 51.6 (C j ), 37.5 (CH 3 ), 29.4, 29.4, 29.2, 29.2, 29.1, 28.9, 26.8, 25 .5 (C b, C c , C d , C e , C f , C g, C h, C i ); HRMS ESI + calcd for C 11 H 24 NO 3 S + (M -N 2 + H) + 250.1471, found 250.1469.
7-Bromo-1-trimethylsilyl-hept-1-yne 14.
A flame dried flask flushed with argon was cooled to -78 °C and charged with a solution of ethynyltrimethylsilane (178 mg, 1.81 mmol, 1 equiv), in dry THF (5 mL). The mixture was stirred at -78 °C for 5 min and n-BuLi was then added dropwise (2.5 M in hexane, 724 µL, 1.81 mmol, 1 equiv). The media was stirred at -78 °C for 1 h and HMPA (315 µL, 1.81 mmol, 1 equiv) was then added. Finally, at -78 °C, to this resulting solution was added dropwise a solution of 1,5dibromopentane (500 mg, 2.17 mmol, 1.2 equiv) in THF (5 mL). The mixture was stirred at -78 °C for 5 min and then at r.t. for 16 h, quenched with a saturated aqueous solution of NH 4 Cl (10 mL) and volatiles were removed in vacuo. The aqueous phase was extracted with DCM (3 × 20 mL) and the combined organic layers were dried over Na 2 SO 4 
12-Bromo-1-trimethylsilyl-dodec-1-yne 15.
A flame dried flask flushed with argon was cooled to -78 °C and charged with a solution of ethynyltrimethylsilane (208 mg, 2.12 mmol, 1 equiv), in dry THF (3 mL). The mixture was stirred at -78 °C for 5 min and n-BuLi was then added dropwise (2.5 M in hexane, 847 µL, 2.12 mmol, 1 equiv). The medium was stirred at -78 °C for 1 h and HMPA (368 µL, 2.12 mmol, 1 equiv) was then added. Finally, at -78 °C, to this resulting pale yellow solution was added dropwise a solution of 1,10-dibromodecane (953 mg, 3.18 mmol, 1.5 equiv) in THF (3 mL). The mixture was stirred at -78 °C for 16 h, quenched with a saturated aqueous solution of NH 4 Cl (10 mL) and volatiles were removed in vacuo. The aqueous phase was extracted with DCM (3 × 20 mL) and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo. Flash chromatography of the residue (Cyclohexane) afforded 15 as a colorless oil (413 mg, 41% yield): R f 0.19 (Cyclohexane); IR (film) 2174w, 1248m, 702s, 840s, 759w; 1 H NMR 13 C NMR δ 107.9 (C 2 ), 84.5 (C 1 ), 34.2 (C a ), 32.9 (C b ), 29.5, 29.2, 28.9, 28.8, 28.3 (C c , C d , C e , C f , C g, C h, C i ), 20.0 (C j ), 0.4 (-Si-(CH 3 ) 3 ); HRMS APPI Calcd for C 12 H 21 Br + (M -TMS + H) + 244.0827, found 244.0822. Spectral data were in agreement with literature. 37 7-O-Acetyl-1-trimethylsilyl-hept-1-yne 16. Potassium acetate (595 mg, 6.07 mmol, 15 equiv) was added to a solution of alkyne 14 (100 mg, 0.40 mmol, 1 equiv), in DMF (6 mL). The reaction mixture was stirred at 80 °C for 12 h, cooled to r.t. and quenched by addition of a saturated aqueous solution of NaHCO 3 (10 mL). The aqueous phase was extracted with ether (4 × 20 mL) and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo. Flash chromatography of the residue (Cyclohexane/EtOAc 9/1) afforded 16 as a colorless oil (65 mg, 71% yield): R f 0.10 (Cyclohexane/EtOAc 9/1); IR (film) 2956w, 2174w, 1742s, 1365w, 1248s, 1049w, 838s, 759m; 1 H NMR 29.6, 29.5, 29.4, 29.2, 28.9, 28.8, 26.1 (C b 13 C NMR δ 168.6 (C 1ar ), 133.9 (C 4ar ), 132.4 (C 2ar ), 123.3 (C 3ar ), 107.9 (C 2 ), 84.4 (C 1 ), 38.2 (C a ), 29.6, 29.3, 29.2, 28.9, 28.8, 28.8, 27 .0 (C b , C c , C d , C e , C f , C g, C h, C i ), 20.0 (C j ), 0.3 (-Si-(CH 3 ) 3 ); HRMS, APCI + Calcd for C 20 H 26 29.6, 29.5, 29.5, 29.3, 29.2, 28.9, 28.7 (C b , C d , C e , C f , C g, C h, C i ), 26 .1 (C c ), 19.9 (C j ), 0.3 (-Si-(CH 3 ) 3 ); HRMS ESI Calcd for C 28 
1-trimethylsilyl-3-[4-O-(benzophenonyl)-benzyl]-prop-1-yne 21.
To a suspension of bromide derivative 20 24 
3-[4-O-(Benzophenonyl)-benzyl]-propadiene 22.
To a solution of alkyne 21 (49 mg, 0.12 mmol, 1 equiv) in dry THF (1.5 mL), was added, at 0 °C, tetrabutyl ammonium fluoride trihydrate. The flashing dark purple solution was stirred 10 min at 0 °C, and then at r.t. for 1 h. After removal of volatiles in vacuo, the crude residue was purified by flash chromatography (Cyclohexane/DCM = 9/1 to 7/3). In these conditions, allene 22 was obtained as white powder (37 mg 13 C NMR δ 63.2 (C j ), 51.6 (C a ), 32.9 (C i ), 29.6, 29.5, 29.5, 29.3, 28.9, 26.8, 25.8 (C b , C c , C d , C e , C f , C g, C h ); HRMS ESI + Calcd for C 10 29.5, 29.5, 29.2, 29.2, 28.9, 28.7, 26.9, 26 .8 (C b, C c , C d , C e , C f , C g, C h, C i ); HRMS APCI + Calcd for C 18 H 25 N 2 O 2 + (M -N 2 + H) + 301.1911, found 301.1911.
General procedure for TMS deprotection, preparation of compounds 8b, 8f, 8h
To a solution of the silylated alkyne (1 equiv) in THF (0.1 M), was added in one portion tetrabutyl ammonium fluoride trihydrate (1.1 to 1.6 equiv). The solution was stirred at r.t. for 1 h and volatiles were removed in vacuo. Flash chromatography of the residue afforded the corresponding terminal alkyne. 29.6, 29.5, 29.5, 29.5, 29.2, 28.9, 28 .7 (C c , C d , C e , C f , C g, C h , C i ), 18.6 (C j ); HRMS APPI Calcd for C 18 13 C NMR δ 84.9 (C 2 ), 68.2 (C 1 ), 63.2 (C a ), 32.9 (C b ), 29.7, 29.6, 29.2, 28.9, 28.6, 25.8 (C c , C d , C e , C f , C g, C h, C i ), 18.5 (C j ); HRMS, APCI + Calcd for C 12 29.6, 29.5, 29.3, 29.2, 28.8, 28.7, 28.6, 26.9 (C b , C c , C d , C e , C f , C g, C h, C i ), 18.5 (C j ); HRMS, ESI + Calcd for C 20 H 26 NO 2 + (M + H) + 312.1958, found 312.1961.
12-Phenyl
3-[4-O-(Benzophenonyl)-benzyl]-prop-1-yne 8g.
To a suspension of protected alkyne 21 (100 mg, 0.25 mmol, 1 equiv) in methanol (3 mL 
12-O-p-Benzophenonyl-dodec-1-yne 8h.
Alkyne 8h was obtained from protected alkyne 19 (54 mg, 0.12 mmol, 1 equiv) according to the general procedure for terminal alkyne synthesis. Flash chromatography of the residue (Cyclohexane/EtOAc 9/1) afforded 8h as a white film (44 mg, 97% yield): R f 0.51 (Cyclohexane/EtOAc 9/1); IR (film) 2919w, 1639s, 1602m, 1307s, 1290m, 1253s, 1175w; 1 H NMR  7.84-7.81 (m, 2H, H 3ar ), 7.77-7.75 (m, 2H, H 7ar ), 7.59-7.55 (m, 1H, H 9ar ), 7.49-7.46 (m, 2H, H 8ar ), 6.96-6.94 (m, 2H, H 2ar 29.6, 29.5, 29.5, 29.3, 29.2, 28.8, 28.6 (C b , C d , C e , C f , C g, C h, C i ), 26.1 (C c ), 18.5 (C j ); HRMS, ESI + Calcd for C 25 
General procedure for Cu(I)-catalyzed azide-alkyne cycloaddition, preparation of compounds 23a-h
To a solution of alkyne 5 (1 equiv) 75.4 (C 5' ), 72.6 (C 3' ), 50.5 (C 9' ), 40.5 (C 5'' ), 31.9 (C 10' ), 30.5 (C 7'' ), 29.6, 29.5, 29.5, 29.4, 29.1, 28.9, 28.9 (C 7'' , C 6', C 11' , C 12' , C 13' , C 14' , C 15' , C 16' ), 25.9, , 84.4 (C 4' ), 82.6 (C 2'' ), 80.9 (C 2' ), 75.4 (C 5' ), 72.7 (C 3' ), 50.4 (C 9' ), 40.5 (C 5'' ), 36.1 (C 18' ), 31.6 (C 10' ), 30.6 (C 7'' ), 29.6, 29.6, 29.5, 29.5, 29.4, 29.1, 28.9, 26 .6 (C 7'' , C 6' , C 11' , C 12' , C 13' , C 14' , C 15' , C 16', C 17' ), 25.9, 25. (dd, 1H, J H4'' -H5''a = 6.0 Hz, J H4''-H5''b = 10.0 Hz, H 4'' ), 4.39-4.29 (m, 2H, H 9' ), 4.20-4.17 (m, 2H, H 2' , H 5' ), 4.00 (dd, 1H, J H3' -H2' = 4.0 Hz, J H3'-H4' = 3.0 Hz, H 3' ), 3.90-3.81 (m, 3H, H 5'' , H 4' ), 3.65 (t, 2H, J H13'-H12' = 6.0 Hz, H 13' ), 3.48 (dd, 1H, J H6'a-H6'b = 14.0 Hz, J H6'a-H5' = 4.0 Hz, H 6'a ), 3.06 (dd, 1H, J H6'b-H6'a = 14.0 Hz, J H6'b-H5' = 10. 5 Hz, H 6'b ), 1.92 (qt, 2H, J H10'-H9' = J H10'-H11' = 7.0 Hz, H 10' ), 1.73-1.64 (m, 2H, H 7'' ), 1.64-1.58 (m, 2H, H 12' ), 1.56-1.50 (m, 2H, H 7'' ), 1.44-1.38 (m, 2H, H 11' ), 0.88 (t, 3H, J H8'' -H7'' = 7. 5 Hz, H 8'' ), 0.87 (s, 9H, -C(CH 3 ) 3 ), 0.84 (s, 9H, -C(CH 3 ) 3 ), 0.83 (t, 3H, J H8'' -H7'' = 7. 5 Hz, H 8'' ), 0.08, 0.07, -0.01 (3s, 12H, -Si-t-Bu-(CH 3 ) 2 ); 13 C NMR δ 168.3 (C 9'' ), 163.2 (C 4 ), 150.6 (C 2 ), 143.1 (C 7' ), 140.0 (C 6 ), 134.5 (C 12'' ), 131.9 (C 10'' ), 123.8 (C 11'' ), 122.3 (C 8' ), 117.7 (C 6'' ), 112.3 (C 1'' ), 103.3 (C 5 ), 87.6 (C 1' ), 86.4 (C 3'' ), 84.6 (C 4'' ), 84.4 (C 4' ), 82.3 (C 2'' ), 80.8 (C 2' ), 75.3 (C 5' ), 72.7 (C 3' ), 62.5 (C 13' ), 50.2 (C 9' ), 40.5 (C 5'' ), 31.9 (C 7'' ), 30.2 (C 10' ), 29.5 (C 11' ), 28.9 (C 6' ), 28.9 (C 7'' ), 25.8, Compound 23e. To a suspension of azide 7e (11.5 mg, 0.043 mmol, 1 equiv), alkyne 5 (55 mg, 0.065 mmol, 1.5 equiv), CuSO 4 . 5H 2 O (1.1 mg, 0.004 mmol, 0.1 equiv) in tert-butanol/H 2 O (1.5 mL/500µL) were successively added sodium ascorbate (2.6 mg, 0.013 mmol, 0.3 equiv) and diisopropylethylamine (16 µL, 0.09 mmol, 2.2 equiv). The resulting brown mixture was sonicated for 5 min, stirred at r.t. for 18 h and diluted with DCM (30 mL) and NH 4 Cl (15 mL). The aqueous phase was extracted with DCM (6 × 30 mL) and the combined organic layers were washed with 10 -3 M solution of tetra-sodium EDTA, dried (Na 2 SO 4 ), filtered and concentrated in vacuo. The residue was then purified by flash chromatography (EtOAc/MeOH 100/0 to 90/10) to afford 23e as a pale red film (20.5 mg, 43% yield): R f 0.10 (EtOAc/MeOH 90/10); [α] D -23 (c 0.5, CH 2 Cl 2 ); IR (film) 2930br, 2853w, 1713s, 1394w, 1100m; 1 H NMR  8. 1H, NH), 2H, H 11'' ), 7.86 (d, 1H , J H6-H5 = 7.0 Hz, H 6 ), 7.79-7.75 (m, 2H, H 12'' ), 7.64-7.54 (br s, 1H, H 8' ), 6.19 (br d, 1H , J H5-H6 = 6.5 Hz, H 5 ), 6.06-5.95 (br s, 1H, H 1' ), 5.38 (s, 1H, H 1'' ), 4.78 (d, 1H , J H2''-H3'' = 6.0 Hz, H 2'' ), 4.70 (d, 1H , J H3''-H2'' = 6.0 Hz, H 3'' ), 4.60-4.48 (m, 3H, H 9' , H 4'' ), 4.28-4.17 (m, 2H, H 2' , H 5' ), 4.06-3.98 (m, 1H, H 3' ), 3.90-3.77 (m, 5H, H 5'' , H 4', H 10' ), 3.77-3.48 (m, 18H, H 6'a , H 6'b , H 11' , H 12' , H 13' , H 14' , H 15' , H 16' , H 17' , H 18' ), 3.11-3.03 (br s, 1H, OH), 1.72-1.63 (m, 2H, H 7'' ), 1.59-1.43 (m, 2H, H 7'' ), 0.89 (t, 3H, J H8'' -H7'' = 7.5 Hz, H 8'' ), 0.87 (s, 9H, -C(CH 3 ) 3 ), 0.84 (s, 9H, -C(CH 3 ) 3 ), 0.83 (t, 3H, J H8'' -H7'' = 7.0 Hz, H 8'' ), 0.08, 0.07, -0.01 (3s, 12H, -Si-t-Bu-(CH 3 ) 2 ); 13 C NMR δ 168.3 (C 9'' ), 163.2 (C 4 ), 150.5 (C 2 ), 140.1 (C 7' ), 140.0 (C 6 ), 134.5 (C 12'' ), 131.9 (C 10'' ), 123.8 (C 11'' ), 123.8 (C 8' ), 117.7 (C 6'' ), 112.3 (C 1'' ), 103.4 (C 5 ), 87.3 (C 1' ), 86.4 (C 3'' ), 84.6 (C 4'' ), 84.5 (C 4' ), 82.4 (C 2'' ), 80.8 (C 2' ), 75.3 (C 5' ), 73.0 (C 3' ), 72. 8, 70.7, 70.6, 70.4, 69.6, 61.7 (C PEG ), 50.5 (C 9' ), 40.5 (C 5'' ), 29.5 (C 7'' ), 28.9 (C 7'' ), 25.9, 25.9 (-C(CH 3 ) 3 ), 18.1, 18.1 (-C(CH 3 ) 3 ), 8.5, 7.5 (C 8'' ), Compound 23f. Triazole 23f was synthesized according to the general procedure for Cu(I)-catalyzed azide-alkyne cycloaddition from alkyne 5 (67 mg, 0.08 mmol) and azide 7f (52.3 mg, 0.14 mmol, 2 equiv). Flash chromatography (Cyclohexane/EtOAc 1/1) afforded 23f as a white foam (57 mg, 61% yield): R f 0.20 (Cyclohexane/EtOAc 1/1); m.p. 114-118 °C; [α] D -29 (c 1.0, CH 2 Cl 2 ); IR (film) 2930m, 1773w, 1701s, 1395m, 1086m, 837m, 721m; 1 H NMR  8.56 (d, 1H , J NH-H5 = 2.0 Hz, NH), 7.89-7.87 (m, 3H, H 11'' , H 6 ), 7.84-7.81 (m, 2H, H 21' ), 7.78-7.74 (m, 2H, H 22' ), 7.72-7.69 (m, 2H, H 12'' ), 7.36 (s, 1H, H 8' ), 6.20 (dd, 1H , J H5-H6 = 8.0 Hz, J H5-NH = 2.0 Hz, H 5 ), 5.96 (d, 1H , J H1'-H2' = 5.5 Hz, H 1' ), 5.35 (s, 1H, H 1'' ), 4.78 (d, 1H , J H2''-H3'' = 6.0 Hz, H 2'' ), 4.68 (d, 1H , J H3''-H2'' = 6.0 Hz, H 3'' ), 4.54-4.51 (m, 1H, H 4'' ), 4.34-4.25 (m, 2H, H 9' ), 4.19-4.16 (m, 2H, H 2' , H 5' ), 3.99 (t, 1H, J H3' -H2' = J H3'-H4' = 3. 5 Hz, H 3' ), 3.88-3.82 (m, 3H, H 5'' , H 4' 1.89-1.84 (m, 2H, H 10' ), 1.69-1.62 (m, 4H, H 17' , H 7'' ), 1.55-1.57-1.42 (m, 2H, H 7'' ), 1.24-1.19 (m, 12H, H 11' , H 12' , H 13' , H 14' , H 15' , H 16' 13 C NMR δ 168.6, 168.2 (C 19' , C 9'' ), 163.2 (C 4 ), 150.5 (C 2 ), 142.9 (C 7' ), 139.9 (C 6 ), 134.5 (C 12'' ), 133.9 (C 22' ), 132.3 (C 20' ), 131.9 (C 10'' ), 123.8 (C 11'' ), 123.3 (C 21' ), 122.0 (C 8' ), 117.7 (C 6'' ), 112.3 (C 1'' ), 103.2 (C 5 ), 87.6 (C 1' ), 86.4 (C 3'' ), 84.5 (C 4'' ), 84.3 (C 4' ), 82.2 (C 2'' ), 80.8 (C 2' ), 75.4 (C 5' ), 72.7 (C 3' ), 50.4 (C 9' ), 40.5 (C 5'' ), 38.2 (C 18' ), 30.5 (C 7'' ), 29.5, 29.4, 29.4, 29.2, 29.1, 28.9, 28.7, 26.9, 26.6 (C 7'' , C 6' , C 10' , C 11' , C 12' , C 13' , C 14' , C 15' , C 16', C 17' ), 25.9, 8.4, 7.5 (C 8'' ), 7.89-7.86 (m, 2H, H 11'' ), 7.85-7.82 (m, 3H, H 6 , H 17' ), 7.77-7.74 (m, 4H, H 12'' , H 22' ), 7.58-7.55 (m, 1H, H 23' ), 7.48 (d, 2H , J H21'-H22' = 8.0 Hz, H 21' ), 7.45 (d, 2H, H 11' ), 7.36 (s, 1H, H 8' ), 7.28 (d, 2H , J H12'-H11' = 8. 5 Hz, H 12' ), 2H, H 16' ), 6.17 (dd, 1H, J H5-H6 = 8.0 Hz, J H5-NH = 2.0 Hz, H 5 ), 5.95 (d, 1H , J H1'-H2' = 6.0 Hz, H 1' ), 5.56 (d, 1H , J H9'a-H9'b = 15.0 Hz, H 9'a ), 5.47 (d, 1H , J H9'b-H9'a = 15.0 Hz, H 9'b ), 5.34 (s, 1H, H 1'' ), 5.14 (s, 2H, H 14' ), 4.78 (d, 1H , J H2''-H3'' = 6.0 Hz, H 2'' ), 4.67 (d, 1H , J H3''-H2'' = 6.0 Hz, H 3'' ), 4.52 (dd, 1H, J H4'' -H5''a = 6.5 Hz, J H4''-H5''b = 9. 5 Hz, H 4'' ), 2H, H 2' , H 5' 5 Hz, H 8'' ), 0.07, 0.07, 0.06, -0.03 (4s, 12H, -Si-t-Bu-(CH 3 ) 2 ); 13 C NMR δ 195.6 (C 19' ), 168.2 (C 9'' ), 162.9 (C 4 ), 162.3 (C 15' ), 150.4 (C 2 ), 143.6 (C 7' ), 139.9 (C 6 ), 138.3 (C 20' ), 137.1 (C 13' ), 134.8 (C 10' ), 134.4 (C 12'' ), 132.7 (C 17' ), 132.1 (C 23' ), 131.9 (C 10'' ), 130.7 (C 18' ), 129.9 (C 21' ), 128.4 (C 22' ), 128.3 (C 11' ), 128.3 (C 12' ), 123.9 (C 11'' ), 122.3 (C 8' ), 117.7 (C 6'' ), 114.9 (C 16' ), 112.5 (C 1'' ), 103.2 (C 5 ), 87.6 (C 1' ), 86.4 (C 3'' ), 84.5 (C 4'' ), 84.5 (C 4' ), 82.2 (C 2'' ), 80.8 (C 2' ), 75.4 (C 5' ), 72.8 (C 3' ), 69.7 (C 14' ), 53.9 (C 9' ), 40.4 (C 5'' ), 29.5 (C 7'' ), 28.9 (C 7'' ), 28.9 (C 6' ), 25.9, 8.5, 7.5 (C 8'' ), 1H, NH), 3H, H 11'' , H 6 ), 2H, H 21' ), 4H, H 12'' , H 25' ), 1H, H 27' ), 7.47 (t, 2H , J H26'-H27' = J H26'-H25' = 8.0 Hz, H 26' ), 7.38 (s, 1H, H 8' ), 6.96-6.93 (m, 2H, H 20' ), 6.20 (dd, 1H , J H5-H6 = 8.0 Hz, J H5-NH = 2.0 Hz, H 5 ), 5.97 (d, 1H , J H1'-H2' = 5.5 Hz, H 1' ), 5.33 (s, 1H, H 1'' ), 4.78 (d, 1H , J H2''-H3'' = 6.0 Hz, H 2'' ), 4.68 (d, 1H , J H3''-H2'' = 6.0 Hz, H 3'' ), 4.53 (dd, 1H , J H4'' -H5''a = 7.0 Hz, J H4''-H5''b = 9.0 Hz, H 4'' ), 4.36-4.26 (m, 2H, H 9' ), 4.20-4.18 (m, 2H, H 2' , H 5' ), 4.03 (t, 1H, J H18' -H19' = 6.5 Hz, H 18' ), 4.00 (t, 1H, J H3' -H2' = J H3'-H4' = 4. 5 Hz, H 3' ), 3.92-3.83 (m, 3H, H 5''a , H 5''b , H 4' ), 3.52 (dd, 1H, J H6'a-H6'b = 14.0 Hz, J H6'a-H5' = 5.0 Hz, H 6'a ), 3.08 (dd, 1H, J H6'b-H6'a = 14.0 Hz, J H6'b-H5' = 11.0 Hz, H 6'b ), 1.92-1.85 (m, 2H, H 10' ), 1.84-1.78 (m, 2H, H 17' ), 1.73-1.61 (m, 2H, H 7'' ), 1.57-1.50 (m, 2H, H 7'' ), 1.48-1.44 (m, 2H, H 16' ), 1.38-1.26 (m, 10H, H 11' , H 12' , H 13' , H 14' , H 15' ), 0.88 (t, 3H, J H8'' -H7'' = 8.0 Hz, H 8'' ), 0.86 (s, 9H, -C(CH 3 ) 3 ), 0.84 (s, 9H, -C(CH 3 ) 3 ), 0.82 (t, 3H, J H8'' -H7'' = 8.0 Hz, H 8'' ), 0.08, 0.08, 0.07, -0.01 (4s, 12H, -Si-t-Bu-(CH 3 ) 2 ); 13 C NMR δ 195.6 (C 23' ), 168.2 (C 9'' ), 163.2 (C 4 ), 162.9 (C 19' ), 150.5 (C 2 ), 142.9 (C 7' ), 139.9 (C 6 ), 138. 5 (C 24' ), 134.5 (C 12'' ), 132.7 (C 21' ), 131.9 (C 27' ), 132.2 (C 21' ), 130.1 (C 10'' ), 129.8 (C 25' ), 128.3 (C 26' ), 123.8 (C 11'' ), 122.2 (C 8' ), 117.7 (C 6'' ), 114.9 (C 20' ), 112.4 (C 1'' ), 103.2 (C 5 ), 87.6 (C 1' ), 86.4 (C 4' ), 84.5 (C 2'' ), 84.4 (C 4'' ), 82.2 (C 2' ), 80.8 (C 3'' ), 75.4 (C 3' ), 72.7 (C 5' ), 68.4 (C 18' ), 50.4 (C 9' ), 40.5 (C 5'' ), 30.5 (C 17' ), 29.6, 29.5, 29.4, 29.2, 29.1, 28.9, 26.6, 26.1 (C 6' , C 10' , C 11' , C 12', C 13' , C 14', C 15', C 16', C 7'' ), 25.9, 8.4, 7.4 (C 8'' ), 
General procedure for the preparation of N-triazoles 24a-h
To a solution of azide 6 (1 equiv) and alkyne partner 8a-h (1 to 2 eq) in tert-BuOH/H 2 O (1.5 mL/500 µL) were successively added CuSO 4 (0.1 equiv), sodium ascorbate (0.3 equiv) and N-diisopropylethylamine (2.2 equiv) . The suspension was sonicated for 5 min to solubilise all reagents. The mixture was stirred at r.t. for 18 h and diluted with DCM (30 mL) and NH 4 Cl (15 mL). The aqueous phase was extracted with DCM (6 × 30 mL) and the combined organic layers were washed with 10 -3 M solution of tetra-sodium EDTA, dried (Na 2 SO 4 ), filtered and concentrated in vacuo. The residue was then purified by flash chromatography to give the corresponding N-triazole 24a-h.
Compound 24a. Triazole 24a was synthesized according to the general procedure for the preparation of N-triazoles from azide 6 (52 mg, 0.06 mmol) and 1-dodecyne 8a (25 mg, 0.12 mmol, 2 equiv) . 75.4 (C 2' ), 71.7 (C 3' ), 50.5 (C 6' ), 40.5 (C 5'' ), 32.9 (C 7'' ), 29.8, 29.8, 29.7, 29.7, 29.5, 29.5, 28.9 (C 7 '' , C 9', C 10' , C 11' , C 12' , C 13' , C 14' , C 15' , C 16' ), 25.8, 25.7 (-C 75.4 (C 5' ), 71.7 (C 3' ), 49.9 (C 9' ), 40.4 (C 5'' ), 36.1 (C 18' ), 31.6 (C 10' ), 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.5 (C 7'' , C 6' , C 11' , C 12' 40.4 (C 5'' ), 32.9 (C 7'' ), 29.7, 29.6, 29.5, 29.5, 29.5, 29.4, 29.4, 28.9 (C 7 '' , C 9', C 10', C 11' , C 12' , C 13' , C 14' , C 15' , C 16' ), 25.8, Compound 24e. Triazole 24e was synthesized according to the general procedure for the preparation of N-triazoles from azide 6 (40 mg, 0.047 mmol) and alkyne 8e ( 134.7 (C 12'' ), 132.8 (C 21' ), 132.0 (C 27' ), 131.9 (C 21' ), 130.1 (C 10'' ), 129.9 (C 25' ), 128.4 (C 26' ), 123.9 (C 11'' ), 122.1 (C 7' ), 118.2 (C 6'' ), 114.3 (C 20' ), 112.8 (C 1'' ), 103.2 (C 5 ), 88.3 (C 1' ), 86.4 (C 4' ), 84.7 (C 2'' ), 82.5 (C 4'' ), 82.2 (C 2' ), 79.2 (C 3'' ), 75.5 (C 3' ), 71.9 (C 5' ), 68.5 (C 18' ), 50.0 (C 9' ), 40.5 (C 5'' ), 29.9, 29.8, 29.7, 29.6, 29.4, 29.1, 27.2, 26.2 (C 6' , C 10' , C 11' , C 12', C 13' , C 14', C 15', C 16', C 17', C 7'' ), 25.9, 25.8 (-C (CH 3 ) General procedure for phthalimide, isopentylidene and TBS groups cleavage.
To a solution of triazole 23a-h or 24a-h (1 equiv), in MeOH (700 µL), was added dropwise an ethanolic solution of methylamine (8.03 M, 400 equiv). The solution was stirred at r.t. for 5 h and volatiles were removed in vacuo. To the crude residue was added pure H 2 O (700 µL) and the resulting suspension was cooled to 0 °C. At 0 °C, TFA (2 mL) was added dropwise. The pale yellow resulting solution was stirred at 0°C for 10 min and then at r.t. for 18 h and then concentrated to dryness. The residue was then purified by semi-preparative reverse phase HPLC to give the corresponding fully deprotected tetrols 25a-h or 26a-h. Yields were given after 2 steps and purification by semi-preparative reverse phase HPLC.
Compound 25a. Compound 25a was synthesized according to the general procedure for phthalimide, isopentylidene and TBS groups cleavage from C-triazole 23a (60 mg, 0.059 mmol). After semi-preparative reverse phase HPLC (method A) and lyophilisation, 25a was obtained as an ammonium trifluoroacetate salt ( 75.8 (C 2' ), 73.9 (C 5' ), 71.5 (C 3' ), 51.5 (C 9' ), 44.3 (C 5'' ), 33.2, 31.5, 30.8, 30.7, 30.5, 30.2, 29.8, 27.6, 23.9 (C 6' , C 10' , C 11' , C 12' , C 13' , C 14' , C 15' , C 16', C 17' ), 14.6 (C 18' ); HRMS, ESI + Calcd for C 27 H 45 N 6 O 9 + (M + H) + 597.3243 found, 597.3248; HPLC, method D, t R = 12.19 min , 98%.
Compound 25b. Compound 25b was synthesized according to the general procedure for phthalimide, isopentylidene and TBS groups cleavage from C-triazole 23b (25.6 mg, 0.023 mmol) . After semipreparative reverse phase HPLC (method A) and lyophilisation, 25b was obtained as an ammonium trifluoroacetate salt (white foam, 9.7 mg, 53% yield): m.p. 129-132 °C; [α] D + 14 (c 0.1, MeOH); IR (film) 2923br, 2852br, 2301w, 1699s, 1592m; 1 H NMR (CD 3 OD),  7.83 (s, 1H, H 8' ), 7.79 (d, 1H, J H6-H5 = 8.0 Hz, H 6 ),7. 24-7.22 (m, 2H, H 20' ), 7.16-7.11 (m, 3H, H 21' 35-1.25 (m, 12H, H 11' , H 12' , H 13' , H 14' , H 15', H 16' ); 13 C NMR (CD 3 OD) δ 166.2 (C 4 ), 152.3 (C 2 ), 144.8 (C 7' ), 144.1 (C 19' ), 142.3 (C 6 ), 129.5 (C 21' ), 129.4 (C 20' ), 126.8 (C 22' ), 125.1 (C 8' ), 111.0 (C 1'' ), 102.6 (C 5 ), 91.7 (C 1' ), 85.5 (C 3'' ), 80.2 (C 4'' ), 79.7 (C 4' ), 76.5 (C 2'' ), 75.8 (C 2' ), 73.9 (C 5' ), 71.5 (C 3' ), 51.5 (C 9' ), 44.3 (C 5'' ), 37.1 (C 18' ), 32.9 (C 17' ), 31.4 (C 10' ), 30.7, 30.6, 30.6, 30.6, 30.4, 30.2, 29.8, 27.6 (C 6' , C 10' , C 11' , C 12' , C 13' , C 14' , C 15' , C 16' ); HRMS, ESI + Calcd for C 33 Mac Farland turbidity standard (approximately 1.10 8 CFU ml -1 ) were prepared in saline solution (NaCl 0.085%) and then diluted 200 fold in MBH. MIC values were determined as the lowest dilution of product showing no visual turbidity.
Molecular docking
All calculations were performed in Discovery Studio 4.0. MraY structure (PDB code: 4J72) was prepared by use of Prepare Protein protocol of DS 4.0 including the cleaning of the protein, the optimization of side-chain conformation for residues with inserted atoms, the removal of water molecules present in PDB structure, the modeling of missing loop regions based on SEQRES information, the prediction of titration site pKs and protonation state of the structure at the specified pH. Flexible ligand/rigid protein docking was performed using CDOCKER. 33 Ligands were prepared using the Prepared Ligand protocol of DS 4.0 including the generation of canonical tautomers, the keeping of only largest fragments, the set of standard formal charges of common functional groups, the generation of kekule structures, enumeration of ionization states at a given pH range, enumeration of tautomers and the generation of a reasonable 3D conformation using Catalyst. Random ligand conformations were generated from the initial ligand structure through high-temperature molecular dynamics. Due to the high flexibility of MraY ligand, we docked for each ligand several conformations previously generated with the BEST algorithm 43 to cover the full range of conformers. The poses showing the lowest energy were retained and clustered according to their binding mode. Three-dimensional snapshots of the docked ligands were generated using Accelrys DS Visualizer.
